Furthermore, sorafenib is applicable for treatment in CML and ALL and represents a distinct target compared with imatinib, a tyrosine kinase inhibitor for the BCR-ABL pathway [26,27,28]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.